title: Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.
abstract: The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma.
  
  
  METHODS
  More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refractory lymphoma patients with a single administration of nonmyeloablative therapy with tositumomab and (131)I-tositumomab. The 16 patients had a mean of 3.1 (range, 1-6) previous chemotherapy and antibody treatments.
  
  
  RESULTS
  Six of 12 relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6-10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after radioimmunotherapy, and 1 patient had a partial response of 10 mo.
  
  
  CONCLUSIONS
  Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies.
authors.affiliation: Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland. Franz.Buchegger@chuv.ch
authors.forename: Franz
authors.initials: F
authors.lastname: Buchegger
authors.forename: Cristian
authors.initials: C
authors.lastname: Antonescu
authors.forename: Claudine
authors.initials: C
authors.lastname: Helg
authors.forename: Marek
authors.initials: M
authors.lastname: Kosinski
authors.forename: John O
authors.initials: JO
authors.lastname: Prior
authors.forename: Angelika Bischof
authors.initials: AB
authors.lastname: Delaloye
authors.forename: Oliver W
authors.initials: OW
authors.lastname: Press
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000528:radiation effects; D001855:Bone Marrow Diseases / Q000209:etiology; D019008:Drug Resistance, Neoplasm; D004739:England; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016499:Radioimmunotherapy; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012074:Remission Induction; D013557:Switzerland; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D007370:Interferon Type I; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; C119496:tositumomab I-131